TITLE

Ischaemic optic neuropathy, transverse myelitis, and epilepsy in an anti-phospholipid positive patient with systemic lupus erythematosus

AUTHOR(S)
Cordeiro, M F; Lloyd, M E; Spalton, D J; Hughes, G R
PUB. DATE
September 1994
SOURCE
Journal of Neurology, Neurosurgery & Psychiatry;Sep1994, Vol. 57 Issue 9, p1142
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66321902

 

Related Articles

  • Simultaneous deep vein thrombosis and transverse myelitis with negative serology as a first sign of antiphospholipid syndrome: a case report and review of the literature. Carter, Dan; Olchovsky, David; Yonath, Hagit; Langevitz, Pnina; Ezra, David // Clinical Rheumatology;Oct2006, Vol. 25 Issue 5, p756 

    Transverse myelitis is a rare manifestation of antiphospholipid syndrome, usually secondary to systemic lupus erythematosus ( Rheum Dis Clin North Am 20:129–158, ). Only about 110 reports of this complication have been reported ( Lupus 10:851–856, ). A connection has been...

  • A CASE REPOST OF CHRONIC URTICARIA IN SYSTEMIC LUPUS ERYTHEMATOSUS ASSOCIATING TRANSVERSE MYELITIS. Deme, Sanda-Maria; Jianu, Dragos Catalin; Calomfirescu, Stefania Kory // Romanian Journal of Neurology;2011, Vol. 10 Issue 1, p52 

    Transverse myelitis may occur in isolation (idiopathic), or in the setting of another illness. Idiopathic transverse myelitis is assumed to be a result of abnormal activation of the immune system against the spinal cord. We report a 40-year-old woman with chronic urticaria and acute transverse...

  • Devic's syndrome and primary APS: a new immunological overlap. Squatrito, D.; Colagrande, S.; Emmi, L. // Lupus;Oct2010, Vol. 19 Issue 11, p1337 

    Neuromyelitis optica (NMO or Devic's syndrome) is a rare autoimmune disease, previously considered a multiple sclerosis variant. The most important laboratory and clinical features are optic myelitis and transverse myelitis, associated with neuromyelitis optica-IgG antibody (NMO-IgG) positivity....

  • Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus. Campos, L.M.A.; Kiss, M.H.; Amico, &Eacte;.A.; Almeida Silva, C.A. // Lupus;2003, Vol. 12 Issue 11, p820 

    The presence of antiphospholipid (aPL) antibodies and antiphospholipid syndrome (APS) was researched in 57 children and adolescents with systemic lupus erythematosus (SLE). The frequency of aPL antibodies was 75.4% (anticardiolipin 70.2% and lupus anticoagulant 29.1%). The positivity for these...

  • Optic nerve involvement in childhood onset systemic lupus erythematosus: Three cases and a review of the literature. Suri, D.; Abujam, B.; Gupta, A.; Rawat, A.; Saikia, B.; Walker Minz, R.; Gupta, V.; Bansal, R.; Kaushik, S.; Singh, S. // Lupus;Jan2016, Vol. 25 Issue 1, p93 

    The ocular system can be affected in systemic lupus erythematosus (SLE) in one third of patients. However, optic nerve involvement is relatively uncommon, but is more so in pediatric SLE patients, where it can occur in 1% of cases. We report three children with SLE who presented with optic nerve...

  • Transverse Myelitis in Patients with Antiphospholipid Antibodies — The Importance of Early Diagnosis and Treatment. Sherer, Y.; Hassin, S.; Shoenfeld, Y.; Levy, Y.; Livneh, A.; Ohry, A.; Langevitz, P. // Clinical Rheumatology;Jun2002, Vol. 21 Issue 3, p207 

    : Transverse myelitis (TM) is a rare manifestation of systemic lupus erythematosus (SLE) and the antiphospholipid syndrome (APS). No uniform therapeutic protocol exists for its treatment, and the prognosis is usually poor. Here we describe four patients having TM associated with antiphospholipid...

  • SLE-associated transverse myelitis successfully treated with Rituximab (anti-CD20 monoclonal antibody). Armstrong, D. J.; McCarron, M. T.; Wright, G. D. // Rheumatology International;Jun2006, Vol. 26 Issue 8, p771 

    The article discusses the case of a systemic lupus erythematosus patient with transverse myelitis, who was unsuccessfully treated with cyclophosphamide, but responded dramatically to infusions of Rituximab. The response to therapy is variable. Patients show little response to aggressive therapy....

  • Optic neuropathy as a presenting feature of systemic lupus erythematosus: two case reports and literature review. Frigui, M; Frikha, F; Sellemi, D; Chouayakh, F; Feki, J; Bahloul, Z // Lupus;Nov2011, Vol. 20 Issue 11, p1214 

    Systemic lupus erythematosus (SLE) may affect the eyes and/or visual system in up to a third of patients; however, optic nerve involvement has been rarely reported. SLE presenting as optic neuropathy is exceptional. We report two new cases of optic neuropathy as a presenting feature of SLE. The...

  • Neuromyelitis optica spectrum disorder in a patient with systemic lupus erythematosus and anti-phospholipid antibody syndrome. Mehta, Lahar R.; Samuelsson, Melissa K.; Kleiner, Anatole K.; Goodman, Andrew D.; Anolik, Jennifer H.; Looney, R. John; Schwid, Steven R. // Multiple Sclerosis (13524585);Apr2008, Vol. 14 Issue 3, p425 

    Neuromyelitis optica (NMO) is a demyelinating disease of the central nervous system characterized by severe episodes of optic nerve and spinal cord inflammation. NMO-IgG (anti-aquaporin-4) has been recently described as a sensitive and specific marker for NMO. As there have been prior published...

  • Rituximab.  // Reactions Weekly;2/7/2009, Issue 1238, p30 

    The article describes two cases of rituximab adverse reaction in women diagnosed with systemic lupus erythematosus (SLE) and anti-phospholipid syndrome (APS). Both patients received two infusions of 1000 milligrams of rituximab as part of a clinical trial. After receiving the drug, the first...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics